MetaCap

BridgeBio Pharma (BBIO) vs Viatris (VTRS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Viatris (VTRS) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 87.7% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with +54.0% for VTRS. Viatris is the larger company by market cap ($22.50 billion vs $14.81 billion), about 1.5 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs -3.0%).

Viatris pays a dividend yielding 2.45%, while BridgeBio Pharma does not currently pay one. Viatris converts more of its revenue into profit, with a net margin of -24.6% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%VTRS+87.67%
+107%+47%-12%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%VTRS+50.08%
+111%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus VTRS key metrics
MetricBBIOVTRS
Share price$76.03$19.63
Market cap$14.81B$22.50B
1-day change-2.75%-1.26%
YTD return-0.60%+57.67%
1-year return+11.63%+87.67%
5-year return+92.24%+53.96%
Forward P/E—6.94
EPS (TTM)$-3.03$-0.53
Dividend yield0.00%2.45%
Annual dividend$0.00$0.48
Revenue (latest FY)$502.08M$14.30B
Revenue growth (YoY)+126.26%-2.98%
Net income (latest FY)$-732.94M$-3.51B
Gross margin95.82%35.06%
Operating margin-104.25%-18.62%
Net margin-145.98%-24.58%
52-week high$93.42$21.20
52-week low$62.50$10.39
Distance from 52-week high-18.61%-7.41%
Analyst consensusstrong_buybuy
Avg. price target upside+40.73%+10.04%
Average volume2.67M9.11M
Shares outstanding194.80M1.15B
Employees1,08130,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VTRS has outperformed BBIO by 76.0 percentage points over the past year.
  • Viatris offers a meaningfully higher dividend yield (2.45% vs 0.00%).
  • Viatris is more profitable, keeping -24.6 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs -2.98%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About Viatris

VTRS stock →

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees

BBIO vs VTRS FAQ

Which is bigger, BridgeBio Pharma or Viatris?

Viatris (VTRS) is larger, with a market capitalization of $22.50B compared with $14.81B for BridgeBio Pharma (BBIO).

Which stock has performed better over the past year, BBIO or VTRS?

VTRS returned +87.67% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, BridgeBio Pharma or Viatris?

Viatris pays a dividend yielding 2.45%, while BridgeBio Pharma does not currently pay a regular dividend.

Are BridgeBio Pharma and Viatris in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons